Masatoshi Kudo

Researcher Next ID · RN-004722

Researcher · Medicine

Osaka, Japan

Not currently recruitingFunding unknown

Research interests

Medicine

Hepatocellular Carcinoma Treatment and Prognosis

Liver Disease Diagnosis and Treatment

Cholangiocarcinoma and Gallbladder Cancer Studies

Pancreatic and Hepatic Oncology Research

Cancer Immunotherapy and Biomarkers

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1915745
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)30207-1
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
PubMed · 2017 · https://doi.org/10.1159/000462153
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31046-2
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)32453-9

No projects listed.